Orforglipron
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Sep 28, 2023 → Jun 5, 2025
NCT ID
NCT06010004About Orforglipron
Orforglipron is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT06010004. Target conditions include Type 2 Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06692348 | Phase 1 | Completed |
| NCT06440980 | Phase 1 | Completed |
| NCT06010004 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes